Weight Control for Cardiac/Circ Problem: 76.5% of denials overturned
In 34 California IMR decisions from 2016 to 2025, reviewers overturned 26 (76.5%). In the last five years: 75.0% of 32. 34 were medical-necessity disputes.
By year (last five)
| Year | Decisions | Overturned |
|---|---|---|
| 2021 | 1 | 100.0% |
| 2023 | 9 | 77.8% |
| 2024 | 15 | 73.3% |
| 2025 | 7 | 71.4% |
What the findings mention
| What the findings mention | Decisions | Overturned | All decisions here |
|---|---|---|---|
| Published evidence citedThe findings refer to peer-reviewed or published evidence. | 13 | 92.3% | 76.5% |
| Guidelines or criteria citedThe findings cite guidelines, criteria or a standard of care. | 6 | 100.0% | 76.5% |
| Records did not supportThe findings say the documentation did not show what was needed (usually an upheld denial). | 4 | 0.0% | 76.5% |
| FDA approval or off-label use discussedThe findings discuss the FDA label status of the treatment. | 3 | 0.0% | 76.5% |
Keyword matches on the reviewer’s findings, not causes. A tag that appears mostly in overturned decisions is worth documenting in an appeal; it is not a guarantee.
From recent overturned decisions
“The physician reviewer found that Nature of Statutory Criteria/Case Summary:A patient has requested authorization and coverage for Wegovy. Wegovy (semaglutide) is a U.S. Food and Drug Administration approved medication for chronic weight management in adults with obesity or those who are overweight with at least one weight related comorbidity, to be used in conjunction with reduced calorie diet and increased …”
“The physician reviewer found that Nature of Statutory Criteria/Case Summary: A patient has requested authorization and coverage for Zepbound. The U.S. Food and Drug Administration (FDA) has approved Zepbound for weight management in patients diagnosed with obesity or overweight with at least one weight-related comorbidity such as high blood pressure, type 2 diabetes, or high cholesterol. One clinical trial evaluated …”
“The physician reviewer found that Nature of Statutory Criteria/Case Summary: A patient has requested authorization and coverage for Zepbound. Clinical guidelines from the American Association of Clinical Endocrinologists emphasize that excessive adiposity can become dysfunctional and predispose patients to the development of medical complications, including diabetes mellitus and non-alcoholic fatty liver disease. The guidelines recommend pharmacotherapy for weight loss for …”
And one the reviewer upheld
“Nature of Statutory Criteria/Case Summary: A patient has requested authorization and coverage for Zepbound. The American Association of Clinical Endocrinologists (AACE) supports medical therapy for the management of obesity due to the increased risk for multiple chronic diseases associated with obesity. Pharmacotherapy for weight loss may be used for patients with a body mass index (BMI) greater than or equal …”
- California only: these are decisions by independent reviewers under California's IMR program (plans regulated by the Department of Managed Health Care). Other states and self-funded employer plans use different reviewers and rules.
- Selection: only denials that a member took all the way to IMR appear. Most denials are never appealed, and the ones that reach an external reviewer are not a random sample.
- Overturned means the reviewer disagreed with the plan; it does not mean the treatment worked or that a similar request will be approved.
- Argument tags are keyword matches on the reviewer's findings. They describe what the findings mention, not why the case was decided.
- Categories are DMHC's own labels (treatment sub-category and diagnosis category); 'Other' is a catch-all and is excluded from rankings.
Source: California Department of Managed Health Care, Independent Medical Review (IMR) Determinations, Trend (CHHS Open Data). Public California government data; Apellica's aggregates and tags are CC BY 4.0.
Questions
How often were Weight Control denials for Cardiac/Circ Problem overturned?
In 34 California IMR decisions from 2016 to 2025, reviewers overturned 26 (76.5%). In the last five years: 75.0% of 32. 34 were medical-necessity disputes.
What should an appeal document, based on these findings?
Whatever the plan's criteria ask for, shown in the record: the treatments already tried and their results, contraindications to the plan's preferred option, the guideline or evidence that supports the request, and the treating clinician's reasoning written to the criteria. The tag table shows which of these the reviewers mentioned most in overturned cases.
Does a California IMR result apply to my plan?
Only California plans regulated by the Department of Managed Health Care go to IMR. Other states and self-funded employer plans use different reviewers, but they weigh the same things.
Independent reviewers reverse plans when the record answers the criteria. Upload the denial letter; a senior reviewer reads it within 24 hours and tells you in writing whether it can be appealed and how. $0 upfront, 10% of what is recovered, nothing if we do not recover. Not a law firm.